AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
AstraZeneca and Daiichi Sankyo have partnered with Summit Therapeutics to explore the potential of their co-developed antibody-drug conjugate (ADC), Datroway…
Oncology
-
-
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
Kyowa Kirin’s wholly owned subsidiary Kyowa Kirin International has signed an exclusive distribution agreement with Knight Therapeutics for Poteligeo (mogamulizumab)…
-
Daiichi Sankyo, MSD withdraw cancer drug application
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at…
-
Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion
Bayer has landed an accelerated US approval for its non-small cell lung cancer (NSCLC) therapy, Hyrnuo (sevabertinib), expanding the drug’s…
-
RevMed’s pancreatic cancer drug breezes through with swift approval
A potentially paradigm-shifting treatment for pancreatic cancer by Revolution Medicines’ (RevMed) named Rasonque (daraxonrasib) has been approved by the US…
-
Johnson & Johnson’s multiple myeloma treatment secures EC approval
The European Commission (EC) has approved an extended use of Johnson & Johnson's Tecvayli (teclistamab), along with daratumumab, to treat…
-
Intismeran autogene a turning point for cancer vaccines
On 19 August, Moderna announced interim analysis data from the Phase III INTerpath-001 trial for intismeran autogene, a personalised mRNA…
-
Novartis and Takeda drugs gain rare blood cancer routine use on NHS
Around 200 patients a year will benefit from consolidating the routine use of two marketed drugs for NHS patients with…
-
EHA26: Epcoritamab improves PFS but not OS in R/R LBCL
Primary results from the global, randomised, Phase III EPCORE DLBCL-1 (EudraCT 2020-003016-27) trial were presented at the European Hematology Association…
-
Parabilis Medicines sets biotech record with $670m IPO
Parabilis Medicines has secured the largest initial public offering (IPO) in biotech history, suggesting that an uptick of upsized public…
